Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAGOH is a highly conserved, small protein that forms the core of the exon junction complex (EJC), a multiprotein assembly deposited on mature mRNA approximately 20 nucleotides upstream of exon-exon junctions following splicing[1][3][5]. It tightly binds to Y14 (RBM8A) and interacts with the mRNA export factor TAP, but not with other EJC components directly[3][5]. MAGOH is essential for post-splicing mRNA processing, including nuclear export, cytoplasmic localization, and particularly nonsense-mediated mRNA decay. It remains associated with mRNA after export from the nucleus[3][5]. In model organisms, loss of magoh results in severe developmental defects and embryonic lethality, underlining its fundamental importance[3]. In humans, MAGOH is not considered a traditional therapeutic target (such as a receptor or enzyme), but is vital for cellular RNA metabolism. No small-molecule drugs are known to modulate its activity.
MAGOH is not directly targeted by drugs; its function is structural and regulatory within the exon junction complex[2][3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mago homolog, exon junction complex subunit (MAGOH).